PDCD1 and cancer: Immune checkpoint blockades (ICBs), especially the inhibitors targeted to programmed cell death-1 (PD-1) or programmed death-ligand 1 (PD-L1), which can release the brakes of the hosts’ immune system to achieve durable clinical responses, have resulted in a transformation of cancer treatment [4].